openPR Logo
Press release

Neurotune completes next funding round

07-30-2008 02:46 PM CET | Health & Medicine

Press release from: Neurotune AG

/ PR Agency: Biotech Consulting
Schlieren, 29th July 2008. Neurotune AG, a Swiss biopharmaceutical company, announces the closing of the fourth funding round. Another single-digit million Swiss francs will accrue to the company. The company will use the increase in capital to advance the development of its therapeutical approach to treat sarcopenia and along with this the diagnostical methods. Part of the capital will be used to extend a developmental pipeline.
The company focuses on the development of a drug to treat sarcopenia, i.e. age-related muscle atrophy. More than ten million people worldwide are affected by this disease. Appropriate lead candidates have been identified already and presumably the preclinical development of the most promising product candidates will start shortly. In addition, the company will intensify its efforts to establish a biomarker for early and decisive clinical diagnosis of sarcopenia, because the currently used methods are inefficient and labor-intensive.

neurotune ag
Wagistrasse 27 a
8952 Schlieren (Zurich)
Switzerland
Phone +41 44 200 21 95
Fax +41 44 200 20 10
www.neurotune.com

Media enquiries
Dr. Holger Bengs
Biotech Consulting
Phone +49 69 6199 4273
Fax +49 69 6199 4249
info@holgerbengs.de

ABOUT NEUROTUNE AG
Neurotune was incorporated in January 2005 as a spin-off from Prionics AG and has its seat in Schlieren (Zurich), Switzerland.
Neurotune develops small-molecular drugs to treat disorders of the human nervous system (peripheral and central). First priority is given to drugs to treat age-related muscle atrophy – Sarcopenia, and a corresponding biomarker.

ABOUT SARCOPENIA
With age, progressive muscle degeneration leads to reduced strength ensuing problems such as frequent falls. The age-related muscle atrophy – Sarcopenia – is defined as the loss of muscle mass and strength with aging, and plays a major role in the pathogenesis of frailty and functional impairment that occurs with the elderly. It correlates with the loss of muscular strength, decreased metabolic rate, gradual reduction of bone density, and decreased aerobic capacity.
The treatment of Sarcopenia is a growing market with no available causal treatment.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neurotune completes next funding round here

News-ID: 49605 • Views: 1048

More Releases from Neurotune AG

Painless future: new members for Board of Directors, funding and clinical result …
Schlieren (Zurich), Switzerland, April 27, 2010. The shareholders of Neurotune AG, a Swiss biopharmaceutical company, have elected Dr. Anders Härfstrand and Heinrich Rotach as new members of the board of directors at their annual general assembly on April 21, 2010. Anders Härfstrand is a medical doctor with extensive experience in neuropharmacology and an excellent track record as executive director in the pharmaceutical industry (e.g. Pharmacia, Pfizer, Serono). Heinrich Rotach has
Neurotune starts Phase II Clinical Trial to treat neuropathic pain
Schlieren (Zurich), Switzerland, 17th August 2009. Neurotune AG, a Swiss biopharmaceutical company, has received MCC ’s (the South African National Regulatory Agency) approval for a Phase II clinical study of neurotune’s lead compound NT-11624 for neuropathic pain caused by treatment with anti-retroviral medication. Approximately 500.000 HIV-patients in the United States and Europe receive anti-retroviral medication. Neurotune’s Phase II trial (8-week, randomized, double-blind, placebo-controlled, parallel group study) will evaluate the safety
Change in the Management of Neurotune AG
Schlieren, 26th January 2009. Neurotune AG, a Swiss biopharmaceutical company, announces a change in the management. Starting March 1st 2009, Dr. Bruno Oesch will take over the position of Chief Executive Officer from Dr. Andreas J. Schulze, who joined Neurotune in 2005 and is holding the position of CEO since 2006. Andreas J. Schulze will leave at his request to take on a fresh challenge in another company shortly. Bruno Oesch
Neurotune successfully completes Phase 1 Trials with its Lead Compound NT-11624
Schlieren, 15th January 2009. Neurotune AG, a Swiss biopharmaceutical company, which has recently acquired two programs in neuropathic pain, announces the successful completion of Phase I for its lead compound NT-11624 developed for treatment of neuropathic and ostheoarthritic pain. NT-11624, dimiracetam, is a selective small molecular NMDA-receptor antagonist, which acts on a new site of the receptor. The studies on 56 healthy volunteers performed in Switzerland have demonstrated excellent tolerability

All 5 Releases


More Releases for Schlieren

Painless future: new members for Board of Directors, funding and clinical result …
Schlieren (Zurich), Switzerland, April 27, 2010. The shareholders of Neurotune AG, a Swiss biopharmaceutical company, have elected Dr. Anders Härfstrand and Heinrich Rotach as new members of the board of directors at their annual general assembly on April 21, 2010. Anders Härfstrand is a medical doctor with extensive experience in neuropharmacology and an excellent track record as executive director in the pharmaceutical industry (e.g. Pharmacia, Pfizer, Serono). Heinrich Rotach has
Neurotune starts Phase II Clinical Trial to treat neuropathic pain
Schlieren (Zurich), Switzerland, 17th August 2009. Neurotune AG, a Swiss biopharmaceutical company, has received MCC ’s (the South African National Regulatory Agency) approval for a Phase II clinical study of neurotune’s lead compound NT-11624 for neuropathic pain caused by treatment with anti-retroviral medication. Approximately 500.000 HIV-patients in the United States and Europe receive anti-retroviral medication. Neurotune’s Phase II trial (8-week, randomized, double-blind, placebo-controlled, parallel group study) will evaluate the safety
Change in the Management of Neurotune AG
Schlieren, 26th January 2009. Neurotune AG, a Swiss biopharmaceutical company, announces a change in the management. Starting March 1st 2009, Dr. Bruno Oesch will take over the position of Chief Executive Officer from Dr. Andreas J. Schulze, who joined Neurotune in 2005 and is holding the position of CEO since 2006. Andreas J. Schulze will leave at his request to take on a fresh challenge in another company shortly. Bruno Oesch
Neurotune successfully completes Phase 1 Trials with its Lead Compound NT-11624
Schlieren, 15th January 2009. Neurotune AG, a Swiss biopharmaceutical company, which has recently acquired two programs in neuropathic pain, announces the successful completion of Phase I for its lead compound NT-11624 developed for treatment of neuropathic and ostheoarthritic pain. NT-11624, dimiracetam, is a selective small molecular NMDA-receptor antagonist, which acts on a new site of the receptor. The studies on 56 healthy volunteers performed in Switzerland have demonstrated excellent tolerability
Neurotune expands its portfolio by acquiring
Schlieren, 18th September 2008. Neurotune AG, a Swiss biopharmaceutical company, announces that the shareholders meeting, held on August 29th 2008, approved of the expansion of its portfolio with two programs in neuropathic pain. The company has reached an agreement with the Italy-based company Brane Discovery Srl. to acquire rights for two programs in neuropathic pain in a combined cash and share transaction. In a recent financing round, which was lead
Neurotune expands its management by taking on an expert for preclinical developm …
Schlieren, 1st August 2007. Neurotune AG has taken on Dr. Jan Willem Vrijbloed for the expansion of its preclinical development division, and has appointed Michael Kregar as the new Chief Financial Officer (CFO). As the director of preclinical and clinical development, Dr. Jan Willem Vrijbloed will be responsible for the development of new medications. Dr Vrijbloed, was born in 1960 in the Netherlands and has more than 15 years of experience